Unknown

Dataset Information

0

Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer.


ABSTRACT: Enzalutamide marks the latest addition to the drugs currently approved by the US Food and Drug Administration for metastatic, castration-resistant prostate cancer (mCRPC). AFFIRMwas a phase III international randomized trial that evaluated the clinical utility of enzalutamide versus placebo in men with mCRPC who have failed prior docetaxel-containing chemotherapy. Enzalutamide showed a remarkable 37% decreased risk of death with a median overall survival of 18.4 months versus 13.6 months for those who received placebo. These findings confirm the validity of further targeting the androgen receptor as a valid therapeutic approach in prostate cancer despite emergence of castration resistance.

SUBMITTER: Aragon-Ching JB 

PROVIDER: S-EPMC3720116 | biostudies-other | 2012 Nov

REPOSITORIES: biostudies-other

altmetric image

Publications

Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer.

Aragon-Ching Jeanny B JB  

Asian journal of andrology 20121008 6


Enzalutamide marks the latest addition to the drugs currently approved by the US Food and Drug Administration for metastatic, castration-resistant prostate cancer (mCRPC). AFFIRMwas a phase III international randomized trial that evaluated the clinical utility of enzalutamide versus placebo in men with mCRPC who have failed prior docetaxel-containing chemotherapy. Enzalutamide showed a remarkable 37% decreased risk of death with a median overall survival of 18.4 months versus 13.6 months for tho  ...[more]

Similar Datasets

| S-EPMC4407758 | biostudies-other
| S-EPMC8288034 | biostudies-literature
| S-EPMC3813614 | biostudies-literature
| S-EPMC3586060 | biostudies-other
| S-EPMC4492664 | biostudies-literature
| S-EPMC9385484 | biostudies-literature
| S-EPMC5468167 | biostudies-literature
| S-EPMC4744713 | biostudies-other
| S-EPMC4247811 | biostudies-literature
| S-EPMC7333874 | biostudies-literature